Novo and Lilly Face Tough Growth in Diabetes, Trade Data Shows December 2, 2016 The global prevalence of diabetes is growing, but can be a tough sector for pharmaceutical companies to make money in as recent results from Novo Nordisk and Eli Lilly demonstrate. Panjiva data shows that U.S. imports of insulin and related equipment fell 15% in the third quarter in dollar ter... Read more →
France
中文